PE20060075A1 - Composiciones farmaceuticas de alisciren - Google Patents
Composiciones farmaceuticas de aliscirenInfo
- Publication number
- PE20060075A1 PE20060075A1 PE2005000288A PE2005000288A PE20060075A1 PE 20060075 A1 PE20060075 A1 PE 20060075A1 PE 2005000288 A PE2005000288 A PE 2005000288A PE 2005000288 A PE2005000288 A PE 2005000288A PE 20060075 A1 PE20060075 A1 PE 20060075A1
- Authority
- PE
- Peru
- Prior art keywords
- alisciren
- tablet
- resulting
- active ingredient
- granulator
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000002461 renin inhibitor Substances 0.000 abstract 1
- 229940086526 renin-inhibitors Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012748 slip agent Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDA A UNA FORMULACION QUE COMPRENDE: A) UN INHIBIDOR DE RENINA TAL COMO ALISCIREN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, DONDE EL INGREDIENTE ACTIVO ESTA PRESENTE EN UNA CANTIDAD QUE VARIA ENTRE 46-60% EN PESO; B) UN LLENADOR TAL COMO CELULOSA MICROCRISTALINA; C) AGENTE DE DESINTEGRACION, LUBRICANTE, AGENTE DE DESLIZ, AGLUTINANTE. UN PROCEDIMIENTO DE PREPARACION COMPRENDE: 1) MEZCLAR EL INGREDIENTE ACTIVO Y ADITIVOS Y GRANULAR DICHOS COMPONENTES CON UN LIQUIDO GRANULACION; 2) SECAR UN GRANULADOR RESULTANTE; 3) MEZCLAR EL GRANULADOR SECO CON EXCIPIENTES DE FASE EXTERNA; 4) COMPRIMIR UNA MEZCLA RESULTANTE PARA FORMAR UNA DOSIS ORAL SOLIDA COMO UNA TABLETA DE NUCLEO; 5) OPCIONALMENTE RECUBRIR UNA TABLETA DE NUCLEO RESULTANTE PARA DAR UNA TABLETA CUBIERTA CON PELICULA. DICHA FORMULACION SUPERA LOS PROBLEMAS RELACIONADOS CON LAS PROPIEDADES DEL ALISCIREN. SON UTILES EN EL TRATAMIENTO DE HIPERTENSION, FALLA CARDIACA CONGESTIVA, ANGINA, INFARTO DE PECHO, DOLOR DE CABEZA, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55387804P | 2004-03-17 | 2004-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060075A1 true PE20060075A1 (es) | 2006-03-20 |
Family
ID=34994415
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000288A PE20060075A1 (es) | 2004-03-17 | 2005-03-15 | Composiciones farmaceuticas de alisciren |
| PE2010000272A PE20110121A1 (es) | 2004-03-17 | 2005-03-15 | Composiciones farmaceuticas de aliskiren |
| PE2014001265A PE20142101A1 (es) | 2004-03-17 | 2005-03-15 | Composiciones farmaceuticas de aliskiren |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2010000272A PE20110121A1 (es) | 2004-03-17 | 2005-03-15 | Composiciones farmaceuticas de aliskiren |
| PE2014001265A PE20142101A1 (es) | 2004-03-17 | 2005-03-15 | Composiciones farmaceuticas de aliskiren |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8617595B2 (es) |
| EP (2) | EP2283826B1 (es) |
| JP (2) | JP2007529456A (es) |
| KR (2) | KR101274855B1 (es) |
| CN (2) | CN1997354B (es) |
| AR (1) | AR048431A1 (es) |
| AU (2) | AU2005224010B2 (es) |
| BR (1) | BRPI0508833A (es) |
| CA (1) | CA2554633C (es) |
| EC (1) | ECSP066807A (es) |
| ES (1) | ES2747941T3 (es) |
| IL (1) | IL177424A0 (es) |
| MA (1) | MA28490B1 (es) |
| MX (1) | MX347617B (es) |
| MY (2) | MY148773A (es) |
| NO (1) | NO343217B1 (es) |
| NZ (1) | NZ548823A (es) |
| PE (3) | PE20060075A1 (es) |
| RU (3) | RU2384328C2 (es) |
| SG (1) | SG153830A1 (es) |
| TN (1) | TNSN06294A1 (es) |
| TW (1) | TWI406656B (es) |
| WO (1) | WO2005089729A2 (es) |
| ZA (1) | ZA200606220B (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60331849D1 (de) * | 2002-11-05 | 2010-05-06 | Glaxosmithkline Llc | Antibakterielle wirkstoffe |
| US20070191487A1 (en) * | 2004-03-17 | 2007-08-16 | Rigassi-Dietrich Petra G | Galenic formulations of organic compounds |
| TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
| GB0605688D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| CA2645260A1 (en) * | 2006-04-03 | 2007-10-18 | Novartis Ag | Renin inhibitors for the treatment of hypertension |
| GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
| EP1891937A1 (en) * | 2006-08-25 | 2008-02-27 | Novartis AG | Galenic formulations of aliskiren |
| CA2563690C (en) * | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
| JP2010508370A (ja) * | 2006-11-07 | 2010-03-18 | ノバルティス アーゲー | ヘミフマル酸アリスキレンの結晶形 |
| JP2010509254A (ja) * | 2006-11-09 | 2010-03-25 | ノバルティス アーゲー | アリスキレンとオロチン酸の塩 |
| JP2010518147A (ja) * | 2007-02-16 | 2010-05-27 | ノバルティス アーゲー | 有機化合物の使用 |
| EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
| US20090082458A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched aliskiren |
| EP2548553A1 (en) * | 2007-09-28 | 2013-01-23 | Novartis AG | Galenical formulations of aliskiren |
| BRPI0817275A2 (pt) * | 2007-09-28 | 2015-06-16 | Novartis Ag | Combinação farmacêutica de alisquireno e valsartana |
| WO2009045795A2 (en) * | 2007-09-28 | 2009-04-09 | Novartis Ag | Galenical formulations of aliskiren and valsartan |
| US20120029083A1 (en) | 2007-11-13 | 2012-02-02 | Teva Pharmaceutical Industries, Ltd. | Polymorphic forms of aliskiren hemifumarate and process for preparation thereof |
| EP2062874B1 (en) | 2007-11-20 | 2014-12-17 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
| CA2724320A1 (en) * | 2008-06-06 | 2009-12-10 | Teva Pharmaceutical Industries Ltd. | Solid states of aliskiren free base |
| EP2143425A1 (de) | 2008-07-11 | 2010-01-13 | Ratiopharm GmbH | Direktverpresste Aliskiren-Tabletten |
| US20100093603A1 (en) * | 2008-07-17 | 2010-04-15 | Kenneth Baker | Use of organic compounds |
| JO3239B1 (ar) * | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
| US9026212B2 (en) | 2008-09-23 | 2015-05-05 | Incube Labs, Llc | Energy harvesting mechanism for medical devices |
| AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| SI2189442T1 (sl) | 2008-11-20 | 2015-03-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopek in intermediati za pripravo aliskirena |
| WO2010086312A1 (en) | 2009-01-28 | 2010-08-05 | Novartis Ag | Galenic formulations of organic compounds |
| EP2340820A1 (en) | 2009-12-16 | 2011-07-06 | KRKA, tovarna zdravil, d.d., Novo mesto | Moisture-activated granulation process |
| EP2216020A1 (en) | 2009-02-05 | 2010-08-11 | KRKA, tovarna zdravil, d.d., Novo mesto | Moisture-activated granulation process |
| EA201190091A1 (ru) | 2009-02-05 | 2012-01-30 | Крка, Товарна Здравил, Д. Д., Ново Место | Активируемый влагой способ грануляции |
| BRPI1009131A2 (pt) * | 2009-03-20 | 2016-03-01 | Novartis Ag | composição farmacêutica compreendendo aliscireno |
| RU2011142081A (ru) | 2009-03-20 | 2013-04-27 | Новартис Аг | Галеновые фиксированные комбинации валсартана и алискирена |
| JP2010280601A (ja) * | 2009-06-04 | 2010-12-16 | Suntory Holdings Ltd | キシロオリゴ糖高含有錠剤 |
| WO2011028919A2 (en) | 2009-09-03 | 2011-03-10 | Teva Pharmaceutical Industries Ltd. | Solid forms of aliskiren hemifumarate and processes for preparation thereof |
| EP2382967A1 (de) | 2010-04-21 | 2011-11-02 | ratiopharm GmbH | Aliskiren in Form einer festen Dispersion |
| US20110268797A1 (en) | 2010-04-30 | 2011-11-03 | Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi | Multicoated aliskiren formulations |
| US20130129791A1 (en) * | 2010-05-04 | 2013-05-23 | Mahmut Bilgic | Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof |
| JP2015537029A (ja) | 2012-11-14 | 2015-12-24 | ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ | 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物 |
| CN103099793B (zh) * | 2013-02-06 | 2015-07-15 | 中国人民解放军第二军医大学 | 片剂及其制备方法 |
| CN103536576B (zh) * | 2013-10-15 | 2015-07-01 | 海南卫康制药(潜山)有限公司 | 阿利吉仑组合物胶囊 |
| RU2545833C1 (ru) * | 2013-12-03 | 2015-04-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПХФА Минздрава России) | Фармацевтическая композиция с антиишемической и антиоксидантной активностью и способ ее получения |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| EP4085902B1 (en) * | 2019-12-31 | 2025-04-30 | Jiangsu Yahong Meditech Co., Ltd. | Pharmaceutical composition containing nitroxoline, nitroxoline tablet, preparation method therefor and use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3039922A (en) * | 1959-08-17 | 1962-06-19 | Carter Prod Inc | Method of administering tablets having decongestant and anti-histaminic activity |
| MY119161A (en) * | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| DE19820801A1 (de) * | 1998-05-09 | 1999-11-25 | Gruenenthal Gmbh | Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten |
| DE60039802D1 (de) * | 1999-02-10 | 2008-09-25 | Pfizer Prod Inc | Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung |
| US6264983B1 (en) * | 1999-09-16 | 2001-07-24 | Rhodia, Inc. | Directly compressible, ultra fine acetaminophen compositions and process for producing same |
| EP1312379A4 (en) | 2000-08-25 | 2004-08-25 | Takeda Chemical Industries Ltd | FIBRINOGENING AGENTS |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| US7316819B2 (en) * | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
| EP1250921A1 (en) * | 2001-04-21 | 2002-10-23 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Fast disintegrating meloxicam tablet |
| JP2003015880A (ja) * | 2001-06-29 | 2003-01-17 | Toshiba Corp | 携帯情報端末およびアドインプログラム起動方法 |
| AU2002363087A1 (en) * | 2001-10-18 | 2003-05-06 | Novartis Ag | Salts formed of an at1-receptor antagonist and a cardiovascular agent |
| US20030114389A1 (en) * | 2001-11-13 | 2003-06-19 | Webb Randy Lee | Combination of organic compounds |
| DK1507558T3 (da) * | 2002-05-17 | 2011-12-05 | Novartis Pharma Ag | Farmaceutisk sammensætning omfattende en renininhibitor, en calciumkanalblokker og et diuretikum |
| PT1517682E (pt) * | 2002-06-28 | 2007-02-28 | Speedel Pharma Ag | Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo |
| US20040002520A1 (en) * | 2002-07-01 | 2004-01-01 | Soderlund Patrick L. | Composition and method for cessation of Nicotine cravings |
-
2005
- 2005-03-15 AR ARP050100999A patent/AR048431A1/es not_active Application Discontinuation
- 2005-03-15 PE PE2005000288A patent/PE20060075A1/es not_active Application Discontinuation
- 2005-03-15 PE PE2010000272A patent/PE20110121A1/es not_active Application Discontinuation
- 2005-03-15 MY MYPI20090494A patent/MY148773A/en unknown
- 2005-03-15 PE PE2014001265A patent/PE20142101A1/es not_active Application Discontinuation
- 2005-03-15 MY MYPI20051084A patent/MY144477A/en unknown
- 2005-03-16 AU AU2005224010A patent/AU2005224010B2/en not_active Ceased
- 2005-03-16 US US10/590,398 patent/US8617595B2/en active Active
- 2005-03-16 EP EP10177494.1A patent/EP2283826B1/en not_active Expired - Lifetime
- 2005-03-16 BR BRPI0508833-0A patent/BRPI0508833A/pt not_active Application Discontinuation
- 2005-03-16 MX MX2012004612A patent/MX347617B/es unknown
- 2005-03-16 NZ NZ548823A patent/NZ548823A/en not_active IP Right Cessation
- 2005-03-16 EP EP05716117A patent/EP1729736A2/en not_active Ceased
- 2005-03-16 KR KR1020067018968A patent/KR101274855B1/ko not_active Expired - Fee Related
- 2005-03-16 CA CA2554633A patent/CA2554633C/en not_active Expired - Fee Related
- 2005-03-16 RU RU2006136090/15A patent/RU2384328C2/ru not_active IP Right Cessation
- 2005-03-16 SG SG200904140-1A patent/SG153830A1/en unknown
- 2005-03-16 KR KR1020137005111A patent/KR101353736B1/ko not_active Expired - Fee Related
- 2005-03-16 CN CN2005800062331A patent/CN1997354B/zh not_active Expired - Fee Related
- 2005-03-16 CN CN2013103391479A patent/CN103462913A/zh active Pending
- 2005-03-16 TW TW094108055A patent/TWI406656B/zh not_active IP Right Cessation
- 2005-03-16 WO PCT/EP2005/002798 patent/WO2005089729A2/en not_active Ceased
- 2005-03-16 JP JP2007503280A patent/JP2007529456A/ja not_active Withdrawn
- 2005-03-16 ES ES10177494T patent/ES2747941T3/es not_active Expired - Lifetime
- 2005-04-29 US US11/119,273 patent/US7683054B2/en not_active Expired - Fee Related
- 2005-06-15 US US11/153,728 patent/US8007824B2/en active Active
-
2006
- 2006-07-27 ZA ZA2006/06220A patent/ZA200606220B/en unknown
- 2006-08-10 IL IL177424A patent/IL177424A0/en not_active IP Right Cessation
- 2006-08-30 EC EC2006006807A patent/ECSP066807A/es unknown
- 2006-09-15 TN TNP2006000294A patent/TNSN06294A1/en unknown
- 2006-09-27 MA MA29347A patent/MA28490B1/fr unknown
- 2006-10-16 NO NO20064670A patent/NO343217B1/no not_active IP Right Cessation
-
2009
- 2009-05-26 AU AU2009202069A patent/AU2009202069B2/en not_active Ceased
- 2009-10-20 RU RU2009138446/15A patent/RU2438661C2/ru not_active IP Right Cessation
-
2011
- 2011-08-25 RU RU2011135405/15A patent/RU2480210C1/ru not_active IP Right Cessation
-
2012
- 2012-06-06 JP JP2012129230A patent/JP5925607B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060075A1 (es) | Composiciones farmaceuticas de alisciren | |
| CO2022017622A2 (es) | Inhibidores de quinasa nek7 | |
| CL2009000662A1 (es) | Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios. | |
| PH12015502134B1 (en) | Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration | |
| AR049000A1 (es) | Formulacion para compresion directa y proceso para la preparacion de una tableta directamente comprimida | |
| AR054234A1 (es) | Composicion farmaceutica para el tratamiento del cancer | |
| PA8616201A1 (es) | Composiciones farmaceuticas de liberacion sostenida | |
| AR054382A1 (es) | Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| CA2716874A1 (en) | A pharmaceutical composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases | |
| CO2023014204A2 (es) | Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
| BRPI0709847B8 (pt) | composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| UY40234A (es) | Compuestos heteroarilo para el tratamiento del dolor | |
| MX2012005689A (es) | Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos. | |
| CO2022019131A2 (es) | Inhibidores de la quinasa nek7 | |
| AR061166A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilferina | |
| UA101407C2 (ru) | Стабильная комбинированная фармацевтическая композиция амлодипина и бисопролола фумарат | |
| AR045719A1 (es) | Formulacion farmaceutica que comprende levotiroxina sodica, celulosa microcristalina y almidon pregelatinizado; uso de la misma para la fabricacion de un medicamento y proceso para preparar dicha formulacion | |
| UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
| CL2004001843A1 (es) | Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax | |
| MX2021015727A (es) | Derivados de piridin-3-ilo. | |
| CL2011001207A1 (es) | Extruidos que contienen al menos una sustancia farmacéuticamente activa en forma de agujas, tal que la relación entre el tamaño de partículas de la sustancia farmacéuticamente activa con forma de agujas y el diámetro de la cadena es de al menos 1:20; composición farmacéutica; y su uso para preparar medicamentos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |